On this page of StockholderLetter.com we present the latest annual shareholder letter from Jaguar Health, Inc. — ticker symbol JAGX. Reading current and past JAGX letters to shareholders can bring important insights into the investment thesis.
200 Pine Street, Suite 400, San Francisco, CA 94104
Tel: 415.371.8300     Fax: 415.371.8311
https://jaguar.health
May 21, 2024
Dear Stockholder:
You are cordially invited to attend the 2024 Annual Meeting of Stockholders (the    Annual Meeting   )
of Jaguar Health, Inc. (the    Company   ) to be held at 200 Pine Street, Suite 400, San Francisco, CA 94104,
on Friday, June 21, 2024, at 8:30 a.m., local time.
At the Annual Meeting you will be asked to (i) elect one (1) Class III director to our Board of Directors
(ii) ratify the appointment of RBSM LLP as the Company   s independent registered public accounting firm
for the fiscal year ending December 31, 2024, (iii) approve, on a non-binding advisory basis, the compensation
paid by us to our named executive officers as disclosed in this proxy statement, (iv) approve an amendment
and restatement of the Company   s 2014 Stock Incentive Plan (the    2014 Plan   ) to increase the number of
shares of Common Stock authorized for issuance under the 2014 Plan by 45,500,000 shares (equivalent to
758,333 shares following the 1-for-60 reverse stock split to be effectuated on May 23, 2024), and (v) approve
a proposal to grant discretionary authority for the Company to adjourn the Annual Meeting, if necessary,
to solicit additional proxies in the event that there are not sufficient votes at the time of the Annual Meeting
to approve proposal (iv).
It is important that your shares be represented and voted whether or not you plan to attend the Annual
Meeting in person. In order to ensure your shares are voted, you may submit a proxy over the Internet, by
telephone or by completing and mailing a proxy card or by completing a voting instruction form provided by
your bank, broker or other financial intermediary. Submitting a proxy over the Internet, by telephone or
by mail will ensure your shares are represented at the Annual Meeting. If you do attend the Annual Meeting,
you may, of course, withdraw your proxy should you wish to vote in person. Please read the enclosed
information carefully before voting.
Sincerely,
Lisa A. Conte
Chief Executive Officer & President
JAGUAR HEALTH, INC.
200 Pine Street
Suite 400
San Francisco, CA 94104
NOTICE OF 2024 ANNUAL MEETING OF STOCKHOLDERS
To Be Held June 21, 2024
NOTICE HEREBY IS GIVEN that the 2024 Annual Meeting of Stockholders (the    Annual Meeting   )
of Jaguar Health, Inc. (the    Company   ) will be held at 200 Pine Street, Suite 400, San Francisco, CA 94104,
on Friday, June 21, 2024, at 8:30 a.m., local time, for the following purposes:
1.
Electing one (1) Class III director (Proposal 1);
2. Ratifying the appointment of RBSM LLP as the Company   s independent registered public
accounting firm for the fiscal year ending December 31, 2024 (Proposal 2);
3. Approving, on a non-binding advisory basis, the compensation paid by us to our named executive
officers as disclosed in the attached Proxy Statement (Proposal 3);
4. Approving an amendment and restatement of the Company   s 2014 Stock Incentive Plan (the    2014
Plan   ) to increase the number of shares of Common Stock authorized for issuance under the 2014 Plan by
45,500,000 shares (equivalent to 758,333 shares following the 1-for-60 reverse stock split to be effectuated on
May 23, 2024) (Proposal 4);
5. Approving a proposal to grant discretionary authority to adjourn the Annual Meeting, if necessary,
to solicit additional proxies in the event that there are not sufficient votes at the time of the Annual Meeting
to approve Proposal 4 (Proposal 5); and
6. Such other business as properly may come before the Annual Meeting or any adjournment or
postponement thereof.
The board of directors is not aware of any other business to be presented to a vote of the stockholders
at the Annual Meeting. Information relating to the above matters is set forth in the attached Proxy Statement,
which such Proxy Statement is incorporated herein by reference.
Stockholders of record at the close of business on May 13, 2024 are entitled to receive notice of and to
vote at the Annual Meeting and any adjournment or postponement thereof.
By Order of the Board of Directors.
Lisa A. Conte
Chief Executive Officer & President
San Francisco, California
May 21, 2024
Information relating to the above matters is set forth in the attached Proxy Statement. Stockholders of
record at the close of business on May 13, 2024 are entitled to receive notice of and to vote at the Annual
Meeting and any adjournment or postponement thereof. If you have questions concerning the proposals in
the Proxy Statement, would like additional copies of the Proxy Statement or need help in voting your shares of
Common Stock, please contact our proxy solicitor Georgeson LLC at 866-821-0284.
Important Notice Regarding the Availability of Proxy Materials for the Stockholder Meeting to be Held on
June 21, 2024. The proxy materials are available at
https://jaguarhealth.gcs-web.com/financial-information/annual-reports
PLEASE CAREFULLY READ THE PROXY STATEMENT. EVEN IF YOU EXPECT TO ATTEND
THE ANNUAL MEETING, PLEASE PROMPTLY COMPLETE, EXECUTE, DATE AND RETURN
THE ENCLOSED PROXY CARD OR VOTING INSTRUCTION FORM IN THE ACCOMPANYING
POSTAGE-PAID ENVELOPE. NO POSTAGE IS NECESSARY IF MAILED IN THE UNITED STATES.
YOU MAY ALSO SUBMIT A PROXY ELECTRONICALLY VIA THE INTERNET OR BY
TELEPHONE BY FOLLOWING THE INSTRUCTIONS ON THE ENCLOSED PROXY CARD OR
VOTING INSTRUCTION FORM. IF YOU SUBMIT A PROXY BY INTERNET OR TELEPHONE,
THEN YOU NEED NOT RETURN A WRITTEN PROXY CARD OR VOTING INSTRUCTION FORM
BY MAIL. STOCKHOLDERS WHO ATTEND THE ANNUAL MEETING MAY REVOKE THEIR
PROXIES AND VOTE IN PERSON IF THEY SO DESIRE (AS DESCRIBED BELOW).
JAGUAR HEALTH, INC.
200 Pine Street
Suite 400
San Francisco, CA 94104
PROXY STATEMENT
FOR THE 2024 ANNUAL MEETING OF STOCKHOLDERS
To Be Held June 21, 2024
GENERAL INFORMATION ABOUT THE ANNUAL MEETING
We are furnishing this Proxy Statement to our stockholders in connection with the solicitation of
proxies by our board of directors to be voted at the 2024 Annual Meeting of Stockholders (the    Annual
Meeting   ) and at any adjournment or postponement thereof. The Annual Meeting will be held at 200 Pine
Street, Suite 400, San Francisco, CA 94104, on Friday, June 21, 2024, at 8:30 a.m., local time.
When used in this Proxy Statement, the terms the    Company,       we,       us,       our    and    Jaguar    refer to
Jaguar Health, Inc.
The Securities and Exchange Commission (   SEC   ) rules require us to provide an annual report to
stockholders who receive this Proxy Statement. Accordingly, we have enclosed our Annual Report on
Form 10-K for the fiscal year ended December 31, 2023 (the    Annual Report   ), which was filed on April 1,
2024, as amended on April 17, 2024, with this Proxy Statement, and we will also provide copies of such
documents to brokers, dealers, banks, voting trustees and their nominees for the benefit of their beneficial
owners of record. Pursuant to rules adopted by the SEC, the Company is also providing access to its proxy
materials over the Internet. All stockholders will have the ability to access the proxy materials at
https://jaguarhealth.gcs-web.com/financial- information/annual-reports.
The date on which the Notice of 2024 Annual Meeting of Stockholders, this Proxy Statement, the
Annual Report and form of proxy card or voting instruction form are first being sent or given to stockholders
is on or about May 29, 2024.
1
 • shareholder letter icon 5/28/2024 Letter Continued (Full PDF)
 • stockholder letter icon 5/31/2023 JAGX Stockholder Letter
 • stockholder letter icon More "Drugs & Pharmaceuticals" Category Stockholder Letters
 • Benford's Law Stocks icon JAGX Benford's Law Stock Score = 85


JAGX Shareholder/Stockholder Letter Transcript:

200 Pine Street, Suite 400, San Francisco, CA 94104
Tel: 415.371.8300     Fax: 415.371.8311
https://jaguar.health
May 21, 2024
Dear Stockholder:
You are cordially invited to attend the 2024 Annual Meeting of Stockholders (the    Annual Meeting   )
of Jaguar Health, Inc. (the    Company   ) to be held at 200 Pine Street, Suite 400, San Francisco, CA 94104,
on Friday, June 21, 2024, at 8:30 a.m., local time.
At the Annual Meeting you will be asked to (i) elect one (1) Class III director to our Board of Directors
(ii) ratify the appointment of RBSM LLP as the Company   s independent registered public accounting firm
for the fiscal year ending December 31, 2024, (iii) approve, on a non-binding advisory basis, the compensation
paid by us to our named executive officers as disclosed in this proxy statement, (iv) approve an amendment
and restatement of the Company   s 2014 Stock Incentive Plan (the    2014 Plan   ) to increase the number of
shares of Common Stock authorized for issuance under the 2014 Plan by 45,500,000 shares (equivalent to
758,333 shares following the 1-for-60 reverse stock split to be effectuated on May 23, 2024), and (v) approve
a proposal to grant discretionary authority for the Company to adjourn the Annual Meeting, if necessary,
to solicit additional proxies in the event that there are not sufficient votes at the time of the Annual Meeting
to approve proposal (iv).
It is important that your shares be represented and voted whether or not you plan to attend the Annual
Meeting in person. In order to ensure your shares are voted, you may submit a proxy over the Internet, by
telephone or by completing and mailing a proxy card or by completing a voting instruction form provided by
your bank, broker or other financial intermediary. Submitting a proxy over the Internet, by telephone or
by mail will ensure your shares are represented at the Annual Meeting. If you do attend the Annual Meeting,
you may, of course, withdraw your proxy should you wish to vote in person. Please read the enclosed
information carefully before voting.
Sincerely,
Lisa A. Conte
Chief Executive Officer & President


JAGUAR HEALTH, INC.
200 Pine Street
Suite 400
San Francisco, CA 94104
NOTICE OF 2024 ANNUAL MEETING OF STOCKHOLDERS
To Be Held June 21, 2024
NOTICE HEREBY IS GIVEN that the 2024 Annual Meeting of Stockholders (the    Annual Meeting   )
of Jaguar Health, Inc. (the    Company   ) will be held at 200 Pine Street, Suite 400, San Francisco, CA 94104,
on Friday, June 21, 2024, at 8:30 a.m., local time, for the following purposes:
1.
Electing one (1) Class III director (Proposal 1);
2. Ratifying the appointment of RBSM LLP as the Company   s independent registered public
accounting firm for the fiscal year ending December 31, 2024 (Proposal 2);
3. Approving, on a non-binding advisory basis, the compensation paid by us to our named executive
officers as disclosed in the attached Proxy Statement (Proposal 3);
4. Approving an amendment and restatement of the Company   s 2014 Stock Incentive Plan (the    2014
Plan   ) to increase the number of shares of Common Stock authorized for issuance under the 2014 Plan by
45,500,000 shares (equivalent to 758,333 shares following the 1-for-60 reverse stock split to be effectuated on
May 23, 2024) (Proposal 4);
5. Approving a proposal to grant discretionary authority to adjourn the Annual Meeting, if necessary,
to solicit additional proxies in the event that there are not sufficient votes at the time of the Annual Meeting
to approve Proposal 4 (Proposal 5); and
6. Such other business as properly may come before the Annual Meeting or any adjournment or
postponement thereof.
The board of directors is not aware of any other business to be presented to a vote of the stockholders
at the Annual Meeting. Information relating to the above matters is set forth in the attached Proxy Statement,
which such Proxy Statement is incorporated herein by reference.
Stockholders of record at the close of business on May 13, 2024 are entitled to receive notice of and to
vote at the Annual Meeting and any adjournment or postponement thereof.
By Order of the Board of Directors.
Lisa A. Conte
Chief Executive Officer & President
San Francisco, California
May 21, 2024
Information relating to the above matters is set forth in the attached Proxy Statement. Stockholders of
record at the close of business on May 13, 2024 are entitled to receive notice of and to vote at the Annual
Meeting and any adjournment or postponement thereof. If you have questions concerning the proposals in
the Proxy Statement, would like additional copies of the Proxy Statement or need help in voting your shares of
Common Stock, please contact our proxy solicitor Georgeson LLC at 866-821-0284.
Important Notice Regarding the Availability of Proxy Materials for the Stockholder Meeting to be Held on
June 21, 2024. The proxy materials are available at
https://jaguarhealth.gcs-web.com/financial-information/annual-reports


PLEASE CAREFULLY READ THE PROXY STATEMENT. EVEN IF YOU EXPECT TO ATTEND
THE ANNUAL MEETING, PLEASE PROMPTLY COMPLETE, EXECUTE, DATE AND RETURN
THE ENCLOSED PROXY CARD OR VOTING INSTRUCTION FORM IN THE ACCOMPANYING
POSTAGE-PAID ENVELOPE. NO POSTAGE IS NECESSARY IF MAILED IN THE UNITED STATES.
YOU MAY ALSO SUBMIT A PROXY ELECTRONICALLY VIA THE INTERNET OR BY
TELEPHONE BY FOLLOWING THE INSTRUCTIONS ON THE ENCLOSED PROXY CARD OR
VOTING INSTRUCTION FORM. IF YOU SUBMIT A PROXY BY INTERNET OR TELEPHONE,
THEN YOU NEED NOT RETURN A WRITTEN PROXY CARD OR VOTING INSTRUCTION FORM
BY MAIL. STOCKHOLDERS WHO ATTEND THE ANNUAL MEETING MAY REVOKE THEIR
PROXIES AND VOTE IN PERSON IF THEY SO DESIRE (AS DESCRIBED BELOW).
JAGUAR HEALTH, INC.
200 Pine Street
Suite 400
San Francisco, CA 94104
PROXY STATEMENT
FOR THE 2024 ANNUAL MEETING OF STOCKHOLDERS
To Be Held June 21, 2024
GENERAL INFORMATION ABOUT THE ANNUAL MEETING
We are furnishing this Proxy Statement to our stockholders in connection with the solicitation of
proxies by our board of directors to be voted at the 2024 Annual Meeting of Stockholders (the    Annual
Meeting   ) and at any adjournment or postponement thereof. The Annual Meeting will be held at 200 Pine
Street, Suite 400, San Francisco, CA 94104, on Friday, June 21, 2024, at 8:30 a.m., local time.
When used in this Proxy Statement, the terms the    Company,       we,       us,       our    and    Jaguar    refer to
Jaguar Health, Inc.
The Securities and Exchange Commission (   SEC   ) rules require us to provide an annual report to
stockholders who receive this Proxy Statement. Accordingly, we have enclosed our Annual Report on
Form 10-K for the fiscal year ended December 31, 2023 (the    Annual Report   ), which was filed on April 1,
2024, as amended on April 17, 2024, with this Proxy Statement, and we will also provide copies of such
documents to brokers, dealers, banks, voting trustees and their nominees for the benefit of their beneficial
owners of record. Pursuant to rules adopted by the SEC, the Company is also providing access to its proxy
materials over the Internet. All stockholders will have the ability to access the proxy materials at
https://jaguarhealth.gcs-web.com/financial- information/annual-reports.
The date on which the Notice of 2024 Annual Meeting of Stockholders, this Proxy Statement, the
Annual Report and form of proxy card or voting instruction form are first being sent or given to stockholders
is on or about May 29, 2024.
1



shareholder letter icon 5/28/2024 Letter Continued (Full PDF)
 

JAGX Stockholder/Shareholder Letter (Jaguar Health, Inc.) | www.StockholderLetter.com
Copyright © 2023 - 2024, All Rights Reserved

Nothing in StockholderLetter.com is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy.